Shire/TKT I2S Hunter Syndrome BLA, MAA Slated For Fourth Quarter
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Transkaryotic Therapies is planning a fourth-quarter BLA submission for its Hunter syndrome enzyme replacement therapy I2S, the firm said June 20